Prafulk Ravi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Praful K. Ravi, MB, BChir, MRCP, discusses the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer, highlighting the use of the targeted radioligand lutetium Lu 177 vipivotide tetraxetan.

Prafulk raviHarvard medical schoolDana farber cancer instituteLank centerGenitourinary oncologyScience summitOnclive tvPrecision medicine in oncology